Biogen Idec Inc (BIIB) 297.08 $BIIB
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ...
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago.
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine.
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years -
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution.
3 Drugs Set to Become Blockbusters in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 10:30AM CDT
Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover blockbusters that fuel industry R&D spending and...
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents.
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Perrigo Misses on Earnings and Sales, Outlook Slashed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:26PM CDT
Perrigo (PRGO) performed disappointingly in the third quarter.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ...
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago.
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine.
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years -
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution.
3 Drugs Set to Become Blockbusters in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 10:30AM CDT
Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover blockbusters that fuel industry R&D spending and...
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents.
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Perrigo Misses on Earnings and Sales, Outlook Slashed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:26PM CDT
Perrigo (PRGO) performed disappointingly in the third quarter.
